+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Albendazole nanocrystals in experimental alveolar echinococcosis: Enhanced chemoprophylactic and clinical efficacy in infected mice



Albendazole nanocrystals in experimental alveolar echinococcosis: Enhanced chemoprophylactic and clinical efficacy in infected mice



Veterinary Parasitology 251: 78-84



Human alveolar echinococcosis is caused by the fox tapeworm Echinococcus multilocularis and is usually fatal if left untreated. Medical treatment with albendazole (ABZ) remains an effective option. However, due to its low aqueous solubility, ABZ is poorly and erratically absorbed following oral administration resulting in low drug levels in plasma and liver distribution. Thus, there arises the need to find a simple, efficient and scalable method to produce new ABZ formulations with increased bioavailability. Bearing this in mind, ABZ nanocrystals (ABZ-NCs) appears to be a useful tool to achieve this goal. The aim of the current study was to investigate the chemoprophylactic and clinical efficacy of an ABZ-NC formulation on mice infected with E. multilocularis. In the chemoprophylactic efficacy study, mean weight of the cysts recovered from the ABZ-NC group was 50% lower than that recorded from untreated mice, whereas the treatment with ABZ suspension did not show preventive effect. The viability of protoscoleces isolated from ABZ-NC treated mice was significantly lower than control groups. In the clinical efficacy studies, both ABZ formulations resulted in a reduction in the mean weight of the cysts obtained from mice, however only the treatment with the nanosuspension revealed significant differences (P < 0.05) compared to the control groups. Treatment with ABZ-NCs reduced the weight of the cysts by 77% and the viability of their protoscoleces to 34%. All these results coincided with the tissue damage determined at the ultrastructural level. The enhanced chemoprophylactic and clinical efficacy of ABZ-NCs observed in this study could be attributed to an increase in the oral bioavailability of the drug. In a next step, we will characterize the cyst concentration profile after the administration of ABZ-NCs in mice infected with E. multilocularis.

(PDF emailed within 0-6 h: $19.90)

Accession: 045671975

Download citation: RISBibTeXText

PMID: 29426481

DOI: 10.1016/j.vetpar.2017.12.022


Related references

Albendazole nanocrystals in experimental alveolar echinococcosis: Enhanced chemoprophylactic and clinical efficacy in infected mice. Veterinary Parasitology 251: 78-84, 2018

Enhanced chemoprophylactic and clinical efficacy of albendazole formulated as solid dispersions in experimental cystic echinococcosis. Veterinary Parasitology 203(1-2): 80-86, 2014

Albendazole-lipid nanocapsules: Optimization, characterization and chemoprophylactic efficacy in mice infected with Echinococcus granulosus. Experimental Parasitology 2019, 2019

Efficacy of Albendazole-Chitosan Microsphere-based Treatment for Alveolar Echinococcosis in Mice. Plos Neglected Tropical Diseases 9(9): E0003950, 2016

Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine. Parasitology 113: 111-121, 1996

Experimental chemotherapeutic management of alveolar echinococcosis communication xi. compared efficacy of mebendazole flubendazole and albendazole treatment. Meditsinskaya Parazitologiya i Parazitarnye Bolezni (2): 15-19, 1987

Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice. Acta Tropica 152: 185-194, 2016

Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. Antimicrobial Agents and ChemoTherapy 55(12): 5861-5867, 2012

Alveolar echinococcosis in China: efficacy of long-term albendazole. Medecine Tropicale 69(5): 433, 2010

Treatment of experimental alveolar echinococcosis with albendazole: A 1H NMR spectroscopic study. Canadian Journal of Zoology 75(2): 198-204, 1997

The experimental chemotherapy of larval alveolar echinococcosis. The search for an optimal regimen of albendazole use. Meditsinskaia Parazitologiia i Parazitarnye Bolezni 1999(1): 52-55, 1999

Imunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole. Parasitology Research 103(4): 919-929, 2008

Immune response of mice with alveolar echinococcosis to therapy with transfer factor, alone and in combination with albendazole. Parasitology Research 105(4): 1067-1076, 2009

Immunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine on mice with alveolar echinococcosis and treated with albendazole. Parasitology Research3: 4, 919-929, 2008

Efficacy of Oxfendazole, Albendazole and Praziquantel against Cystic Echinococcosis in naturally infected sheep. 2007